Bioxytran Releases Positive Top-line Results from Phase 2 Trial of Galectin Antagonist on COVID-19 Patients in medRxiv Pre-print
Complete elimination of viral load in 100% of patients at day 7 vs 6% in placebo (p=.001) Complete elimination of viral load in 88% of patients at day 3 vs 0% in placebo (p=.001) Treated population experienced no viral rebounds within the 14-day observation period Boston, MA – November 16, 2022 – BIOXYTRAN, INC. […]
Bioxytran Scientific Advisor Releases New Book on Brain Metabolism
The book contains all aspects of brain energy metabolism and other physiological functions related to Cortical Spreading Depression which is the essence of how the brain consumes oxygen. Boston, MA – October 25, 2022 – BIOXYTRAN, INC. (OTCQB:BIXT), (the “Company”), a clinical stage biotechnology company developing oral drugs to treat COVID-19 and other viral causing […]
